Naproxen

Article Details

Citation

Copy to clipboard

Brutzkus JC, Varacallo M

Naproxen

.

PubMed ID

30247840 [ View in PubMed

]

Abstract

Naproxen was initially approved in 1976 for prescription use only and remained a prescription drug until it was approved as an over-the-counter (OTC) medication in 1994. Naproxen is FDA-approved for the treatment of acute gout, ankylosing spondylitis, bursitis, polyarticular juvenile idiopathic arthritis, osteoarthritis, tendonitis, rheumatoid arthritis, pain, and primary dysmenorrhea. It is the first-line treatment for acute gouty arthritis, osteoarthritis, musculoskeletal pain and inflammation and dysmenorrhea. While naproxen and other NSAIDs are approved for the treatment of inflammatory arthropathies such as rheumatoid arthritis and ankylosing spondylitis, they do not alter the course of the disease nor do they prevent joint and soft tissue destruction that are common sequelae of these diseases. Disease-modifying anti-rheumatic drugs (DMARDs) have become the first-line treatment for inflammatory arthropathies, and NSAIDs such as naproxen are used as adjunctive treatments.

DrugBank Data that Cites this Article

Drugs

Naproxen

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Naproxen	Prostaglandin G/H synthase 1	Protein	Humans	Yes	Inhibitor	Details
Naproxen	Prostaglandin G/H synthase 2	Protein	Humans	Yes	Inhibitor	Details